Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ANI Pharmaceuticals Strengthens CDMO Business | Contract Pharma

What are you searching for?

Sign in
Breaking News

ANI Pharmaceuticals Strengthens CDMO Business

Acquisition of Novitium Pharma for $163.5 million also bolsters R&D engine and generics portfolio.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ANI Pharmaceuticals has struck a $163.5 million deal to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. ANI’s board has approved and the acquisition is expected to close in the second half of 2021.
 
“Strengthening our well-established generics business with enhanced development capabilities and increased focus on niche opportunities is a key pillar of ANI’s growth strategy,” said Nikhil Lalwani, president and chief executive officer, ANI. “The acquisition of Novitium aligns with this strategy, adding a best-in-class R&D engine that delivers sustainable growth through new product launches and offering upside through niche 505(b)(2) opportunities. The addition of a U.S. based, state-of-the-art manufacturing facility and enhanced scale to our CDMO business are other attractive advantages of this acquisition.”
 
R&D Engine Fuels Sustainable Growth
Novitium anticipates launching more than 25 additional products in 2021 and 2022, including products with U.S. FDA Competitive Generic Therapy (CGT) designation. The company currently has 21 abbreviated new drug applications (ANDAs) filed with the FDA and more than 30 additional products under development. Integration of Novitium’s R&D operations will establish a center of excellence for ANI’s generics product development program.
 
Expands ANI’s R&D Pipeline Focused on Niche Opportunities
Novitium is currently advancing three 505(b)(2) candidates in oncology and hypertension. These 505(b)(2) products will build on ANI’s increasing focus on niche opportunities, including its first Paragraph IV filing in 2020 and the filing of injectables ANDAs in 2021.
 
Enhances Scale of CDMO Business and U.S.-based Manufacturing Capacity
Novitium adds nine new customers to ANI’s growing CDMO business. Additionally, Novitium brings with it a 50,000 square foott East Windsor, NJ facility, including 27 manufacturing suites and eight clinical suites supporting R&D, commercial manufacturing and packaging. An ongoing 20,000 square foot building expansion will add 18 new manufacturing suites. Novitium’s annual production capacity is approximately two billion units in aggregate across tablets, capsules, liquid suspensions and solutions, powders and powder for oral suspension, controlled release and potent compounds.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters